Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Merck's (MRK) odanacatib osteoporosis drug significantly increased hip and spine bone mineral...

  • Sunday, October 14, 2012, 7:26 AM ET
    Merck's (MRK) odanacatib osteoporosis drug significantly increased hip and spine bone mineral density in a phase two trial of post-menopausal women who had previously taken the company's Fosamax treatment. "Odanacatib may be a viable alternative for patients who need continued therapy and who want benefits beyond what they (already) received," Merck said. (PR)
Track new comments on this story

This news story has 1 comment:

  •  
    The drug stocks are holding up like a champ. I was going to purchase MRK at 42. I am looking at LLY just on evaluation and dividend. I also like LFC; A Chinese Health Care play, but it's yealy dividend was almost cut in half. Plus I don't know what I am looking at with ADR's. Any suggestions out there.
    14 Oct 2012, 08:24 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »